Stada on the prowl for new deals

Germany's Stada Arzneimittel says it's checking out potential takeover targets, looking to continue its recent series of acquisitions, Forbes reports. The generics maker said it may have to raise new capital for the deals so it can maintain its equity ratios.

Stada has been expanding in eastern Europe through takeovers to combat a shrinking generics market at home in Germany. Among its buys: Hemofarm of Serbia, which it bought for $780 million, and Russia's Makiz. Still, the company isn't doing badly at home: Its domestic market lost 3 percent overall last year, but Stada managed to grow its own domestic sales by 20 percent. On the whole, its sales rose by 26 percent to $2.48 billion.

- check out the Forbes coverage

Related Articles:
Stada sells off U.S. sub, exits market. Report
Stada buys Russian pharma group. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.